Get to know our clinical trials
Clinical trial to evaluate the efficacy and safety of new immunomodulators in monotherapy and in combination with antineoplastic agents in patients with advanced hepatobiliary cancer (GEMINI-HCC).
THE AIM OF THIS TRIAL IS TO OBTAIN MORE INFORMATION ON THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS AND IMMUNOGENICITY OF MEDI5752 AND, ALSO, TO BETTER UNDERSTAND THE DISEASE STUDIED AND THE ASSOCIATED HEALTH PROBLEMS.
Technical Summary
- PHASE II, OPEN-LABEL, MULTIDRUG, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NEW IMMUNOMODULATORS IN MONOTHERAPY AND IN COMBINATION WITH ANTINEOPLASTIC AGENTS IN PATIENTS WITH ADVANCED HEPATOBILIARY CANCER (GEMINI-HCC)
- Code EudraCT: 2022-502317-29-00
- Protocol number: D7987C00001
- Promoter: Astra Zeneca AB
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.